Latest Bio-Gene Technology (Asx:Bgt) News

Bio-Gene Technology Limited has raised $338,500 through a Share Purchase Plan, contributing to a total capital raise of $2.45 million to advance its bio-insecticide products.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.